New Hope for Lung Cancer Patients With a HER2 Genetic Mutation
October 18, 2025
October 18, 2025
LONDON, England, Oct. 18 -- The Royal Marsden National Health Service Foundation Trust issued the following news on Oct. 17, 2025:
* * *
New hope for lung cancer patients with a HER2 genetic mutation
A trial testing the use of the targeted drug zongertinib as a first line treatment for lung cancer patients with a HER2 genetic mutation has shown significant findings, according to data presented at the European Society of Medical Oncology (ESMO) Congress 2025 . . .
* * *
New hope for lung cancer patients with a HER2 genetic mutation
A trial testing the use of the targeted drug zongertinib as a first line treatment for lung cancer patients with a HER2 genetic mutation has shown significant findings, according to data presented at the European Society of Medical Oncology (ESMO) Congress 2025 . . .